

Drug Utilization Review Board

Meeting Minutes

Thursday, July 12, 2018
7:15 a.m. to 8:30 a.m.
Cannon Health Building
Room 125

Board Members Present:

Jennifer Brinton, MD
Eric Cannon, PharmD, FAMCP
Neal Catalano, PharmD
Aesha Drozdowski, PharmD

Kim Michelson, DDS
Kumar Shah, MSc, Peng, Board Chair
Susan Siegfried, MD
Sharon Weinstein, MD

Board Members Excused:

Ben Berrett, PharmD

Katheryn Smith, PharmD

Dept. of Health/Div. of Health Care Financing Staff Present:

Robyn Seely, PharmD
Bryan Larson, PharmD

Merelynn Berrett, RN
Heather Santacruz, RN

University of Utah Drug Regimen Review Center Staff Presenter:

Valarie Gonzales, PharmD

Other Individuals Present:

Elena Martinez Alonso, U of U
Joanne LaFleur, UofU
Gregg Gittus, Alkermes
Ari Azamyan, IMC
Valerie Ng, Indivir

Rhonda Clark, Indivior
Rob Booth, Allergan
Jason Bott, Lilly
Lori Howarth, Bayer

Meeting conducted by: Kumar Shah

- 1. Welcome & Housekeeping:** Kumar Shah opened the meeting and reminded everyone to sign the Board and Guest rosters.
- 2. Review and Approval of June Minutes:** Eric Cannon made a motion to approve the June minutes. Kim Michelson seconded the motion. Sharon Weinstein abstained due to absence, all others in favor; motion passed.
- 3. Annual Declaration of Conflicts of Interest:** Board members sign a yearly statement of actual or potential conflicts of interest with Board activities. Robyn Seely has received forms from some, but not all Board members.
- 4. Pharmacy and Therapeutics Committee Report:** Bryan Larson informed the Board that the P&T committee discussed hydroxy-methylglutaryl-coenzyme A reductase inhibitors ("statins") in June, and will be discussing Hemophilia Factor VIII in July.

5. Sublocade (buprenorphine injection)

a. Information:

Valerie Gonzales presented peer-reviewed research regarding safety and efficacy, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.

b. Public Comment: Valerie Ng, Indivior

Sublocade treatment is considered a success if patient urine samples and self-reports are opioid-free 80% of the time. The REMS program is to ensure that the product stays in the hands of health care professionals; it does not address patient monitoring (e.g. liver function tests).

c. Board Discussion:

Aesha Drozdowski expressed concern about patient liver function. Sharon Weinstein doesn't believe that liver function is routinely checked in patients using buprenorphine products.

Eric Cannon asks if we need a prior authorization (PA) at all. To get this drug, the prescriber needs an XDEA number, the prescriber and pharmacy both need to be enrolled in the REMS programs. Is that enough control? What about other drugs – Vivitrol? Buprenorphine? Oral buprenorphine and buprenorphine/naloxone products?

Robyn Seely gave a short background of the Utah Medicaid PA history of the drugs above.

Sharon Weinstein asked why the proposed Sublocade PA criteria includes a question about if the drug will be paid via "buy and bill" or pharmacy point of sale. Robyn Seely clarified that Utah Medicaid gives and processes in-clinic and in-pharmacy PAs differently, and can better prevent double billing, if we know in advance where the bill will originate.

d. Board Action:

1. Motion:

- a)** Remove PA criteria from Sublocade and from Vivitrol.
- b)** Robyn Seely to re-review in 6 months
- c)** Motion to Approve: Sharon Weinstein. Second: Eric Cannon. All in favor.

e. Further Discussion: The Board suggests revisiting oral buprenorphine and buprenorphine/naloxone products, with the intent of removing their PA criteria.

Opioid, alcohol, and general substance abuse were discussed. Board members appreciate the increased public awareness of substance abuse issues and various interest groups' efforts to address substance abuse. The Board is eager to learn how their recommendations above are received by the Department of Health.

- 6. Public Meeting Adjourned:** Aesha Drozdowski motioned to close the meeting. Neal Catalano seconded the motion. All in favor.

Audio recordings of DUR meetings are available online at: <https://medicaid.utah.gov/pharmacy/drug-utilization-review-board?p=DUR%20Board%20Audio%20Recordings/>